Enrollment is complete in the two highest dose groups in a phase 1/2 clinical trial evaluating an adeno-associated virus-based gene therapy for the treatment of X-linked retinitis pigmentosa, according to a press release from Applied Genetic Technologies Corporation.
The open-label, dose escalation trial is evaluating the safety and efficacy of AGTC-501 in patients with XLRP due to a mutation in the RPGR gene.
“We expect that the information that will be obtained from the two additional dose groups will help to reinforce the data generated to date and previously reported (Read more...)
Uncategorized